NCT00356447 - Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms. | Biotech Hunter

Enrollment

249

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions

Vasomotor Symptoms

Interventions

DRUG

Estradiol/DRSP (Angeliq, BAY86-4891)

Drospirenone (DRSP) 2mg and Estradiol 1mg. One cycle consists of 28 days. One tablet daily for 28 days given for a total of 4 cycles. Oral administration.

DRUG

Placebo

Same administration.

Trial Locations (9)

100020

Beijing

100034

Beijing

100083

Beijing

100730

Beijing

200011

Shanghai

210029

Nanjing

250012

Jinan

400010

Chongqing

430032

Wuhan